Eric L. Dobmeier
Net Worth

Last updated:

What is Eric L. Dobmeier net worth?

The estimated net worth of Mr. Eric L. Dobmeier is at least $5,684,829 as of 24 Apr 2023. He has earned $2,205,279 from insider trading and has received compensation worth at least $3,479,550 in Chinook Therapeutics, Inc..

What is the salary of Eric L. Dobmeier?

Mr. Eric L. Dobmeier salary is $695,910 per year as Pres, Chief Executive Officer & Director in Chinook Therapeutics, Inc..

How old is Eric L. Dobmeier?

Mr. Eric L. Dobmeier is 56 years old, born in 1969.

What stocks does Eric L. Dobmeier currently own?

As insider, Mr. Eric L. Dobmeier owns shares in one company:

Company Title Shares Price per share Total value
Chinook Therapeutics, Inc. (KDNY) Pres, Chief Executive Officer & Director 301,138 $0 $0

What does Chinook Therapeutics, Inc. do?

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

KDNY logo
KDNY
Chinook Therapeutics, Inc.

Eric L. Dobmeier insider trading

Chinook Therapeutics, Inc.

Mr. Eric L. Dobmeier has made 6 insider trades between 2020-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 60,000 units of KDNY stock on 1 Dec 2022. As of 24 Apr 2023 he still owns at least 301,138 units of KDNY stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 25,000 $0.42 $10,500
Sale
Common Stock 1,200 $22.26 $26,711
Sale
Common Stock 23,800 $21.58 $513,533
Option
Common Stock 25,000 $0.42 $10,500
Option
Common Stock 20,248 N/A N/A
Sale
Common Stock 8,097 $23.75 $192,296
Option
Restricted Stock Units 20,248 N/A N/A
Option
Restricted Stock Unit 24,999 N/A N/A
Option
Common Stock 24,999 N/A N/A
Sale
Common Stock 7,688 $24.68 $189,755
Option
Stock Option (Right to Buy) 25,000 $0.42 $10,500
Sale
Common Stock 25,000 $24.55 $613,625
Option
Common Stock 25,000 $0.42 $10,500
Option
Stock Option (Right to Buy) 30,000 $0.35 $10,500
Option
Common Stock 30,000 $0.35 $10,500
Option
Common Stock 60,000 $0.42 $25,200
Option
Stock Option (Right to Buy) 60,000 $0.42 $25,200
Sale
Common Stock 30,000 $22.31 $669,360
Option
Common Stock 30,796 N/A N/A
Option
Restricted Stock Units (RSU) 30,796 N/A N/A
Purchase
Common Stock 5,000 $13.03 $65,150
Option
Common Stock 20,247 N/A N/A
Option
Restricted Stock Units (RSU) 20,247 N/A N/A
Option
Common Stock 40,000 $0.35 $14,000
Option
Stock Option (Right to Buy) 40,000 $0.35 $14,000
Option
Common Stock 30,796 N/A N/A
Option
Restricted Stock Units (RSU) 30,796 N/A N/A
Purchase
Common Stock 2,000 $12 $24,000
Purchase
Common Stock 3,000 $12 $36,000
Purchase
Common Stock 7,000 $11.74 $82,166
Option
Stock Option (Right to Buy) 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Option
Stock Option (right to buy) 20,000 $0.35 $7,000
Option
Common Stock 20,000 $0.35 $7,000
Purchase
Common Stock 2,000 $13.08 $26,150
Purchase
Common Stock 2,000 $13.08 $26,150
Purchase
Common Stock 929 $13.67 $12,699
Purchase
Common Stock 571 $13.69 $7,817
Purchase
Common Stock 500 $13.5 $6,750
Purchase
Common Stock 2,500 $13.75 $34,375
Purchase
Common Stock 2,000 $13.86 $27,720

Chinook Therapeutics key executives

Chinook Therapeutics, Inc. executives and other stock owners filed with the SEC: